ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy.
about
The effect of ABCB1 polymorphisms on the outcome of breast cancer treatmentAssociation between PNPLA3 rs738409 polymorphisms and risk of hepatocellular carcinoma and its development in patients with cirrhosis: a meta-analysisA Systematic Framework for Drug Repositioning from Integrated Omics and Drug Phenotype Profiles Using Pathway-Drug NetworkAssociation of ABCB1 and SLC22A16 Gene Polymorphisms with Incidence of Doxorubicin-Induced Febrile Neutropenia: A Survey of Iranian Breast Cancer PatientsABCB1 and ABCC2 and the risk of distant metastasis in Thai breast cancer patients treated with tamoxifen.Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel.Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice.Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature.Drug transporters in breast cancer: response to anthracyclines and taxanes.A long non-coding RNA contributes to doxorubicin resistance of osteosarcoma.Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review.Assessment of Pharmacogenomic Panel Assay for Prediction of Taxane Toxicities: Preliminary Results.PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways.Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients.Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand.
P2860
Q26749954-BEDEA45B-A016-400C-9FCA-28F9BC4CD226Q26801941-F0CC14CE-1EAD-4DC2-B2F7-1A9FEC701A5BQ28817426-81A63FB5-738B-4563-99EE-E3EBE9D619F6Q36236476-DAC6E5FD-3EA1-4A95-A3A1-4B7C475822CFQ36808170-FD4FB48D-40AE-4668-A75D-0D544078919EQ37187663-15B2C3C0-2686-4DAF-AE46-BAC4D207E29CQ37602839-FFBEAE90-3580-4E19-9505-5C2B5771D19BQ38414396-7C77E5B3-779B-4219-B3CC-FDD25606F260Q38575008-9D943AD0-ADE6-4A04-97D3-0031668BAE86Q38832378-EFA5BCE1-A70D-492C-BD6F-CF6B93F308F7Q38933314-398F1BBD-799B-4845-B83F-C88A3FF9C689Q47157497-ADCB56B8-D7A6-4158-AAE5-C4DF0C2ECE78Q47289144-B983D8CA-9F3F-447E-BC83-67BA8EB8A130Q51744122-0A993D49-B6F2-48B2-AE42-714A494F5F2AQ51782486-A0B0D3C8-D449-44B8-A9BC-420DB2EE9C17Q55497899-C2D0D824-5BB4-4F03-A725-AC4263A8EA9A
P2860
ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
ABCB1 polymorphism as prognost ...... icin neoadjuvant chemotherapy.
@ast
ABCB1 polymorphism as prognost ...... icin neoadjuvant chemotherapy.
@en
type
label
ABCB1 polymorphism as prognost ...... icin neoadjuvant chemotherapy.
@ast
ABCB1 polymorphism as prognost ...... icin neoadjuvant chemotherapy.
@en
prefLabel
ABCB1 polymorphism as prognost ...... icin neoadjuvant chemotherapy.
@ast
ABCB1 polymorphism as prognost ...... icin neoadjuvant chemotherapy.
@en
P2093
P2860
P356
P1433
P1476
ABCB1 polymorphism as prognost ...... icin neoadjuvant chemotherapy.
@en
P2093
Bhumsuk Keam
Do-Youn Oh
Hee-Jun Kim
Hye Seon Ham
In Ae Park
In-Jin Jang
Jee Hyun Kim
Kyung Hun Lee
Seock-Ah Im
Tae Yong Kim
P2860
P356
10.1111/CAS.12560
P577
2014-12-08T00:00:00Z